The wise choice for your eyes… since 2007

Categories , Tag

Can-C Eye Drops for Dogs

$39.00 or $37.05 / month

  • Reverses Cataracts*
  • Promotes ocular healing*
  • Acts as a potent antioxidant*
  • Original 1% N-acetylcarnosine formula
  • Addresses root cause of dry eyes*
  • Soothing Lubricating Eyedrops*

Clinical studies show initial results in only 3 months time!
Optimal Results within 6 – 12 months!

  • (4 – 8 week supply) 1 – 2 boxes @ $39.00/box = 10% Savings!
  • (3 – 4  month supply) 3 – 4 boxes @ $35.00/box = 19% Savings!
  • (6 – 8  month supply) 6 – 8 boxes @ $31.50/box = 25% Savings!
  • Two (5ml) vials per box
  • Based on applying 3 drops daily to each eye.
  • Quantity discounts applied in cart
Subscribe & Save

Can-C™ is a proprietary form of N-acetylcarnosine, a highly specific intraocular released form of carnosine which acts as both a stabilizer and carrier for safe delivery into the aqueous humor of the eye. Once delivered into the aqueous humor this bio-identical molecule becomes highly active in the reduction of free radicals, oxidative stress and lens glycosylation.

Many dog owners, including veterinarians, are now using this product to effectively treat their pet’s cataract condition. The results of the Russian clinical trials with dogs were quite promising, with no negative side effects. Can-C appears to work even better in dogs than it does in humans, according to Dr. Babizhayev. Remember to consult your veterinarian before administering any unapproved drug to your animals.

How to administer Can-C™ Eye Drops To Your Dog

Can-C™ Ingredients:

  • N-Acetyl-Carnosine (NAC) 1.0% (approved by IVP)
  • Glycerin (lubricant) 1.0%
  • Carboxymethylcellulose sodium (lubricant) 0.3%


  • Sterile Water (Ophthalmic Grade Isotonic Solution, pH 6.3 to 6.5)
  • Buffers: Potassium Bicarbonate and Boric Acid
  • Purified Benzyl Alcohol (Preservative) 0.3%
For bundles containing Can-C Eye Drops for Dogs, please click here

Guaranteed Safe Checkout

Safe & Effective Ingredients

The healthy eye contains high levels of L-Carnosine. Interestingly, the eyes of those suffering from degenerative ocular diseases such as cataracts were found to be grossly deficient in this essential ocular antioxidant. Can-C™ replenishes the eye’s natural levels of this potent, natural antioxidant.

Clinically Proven Results

After 6 months, placebo-controlled clinical studies showed that eyes treated with the specific purified N-acetyl-carnosine:

  • 90% showed improvements in visual acuity
  • 89% had improvement of glare sensitivity.
  • 42% had an improvement of transmissivity of the lens.
  • These improvements lasted for the duration of treatment.

Enhancing the Eye's Restorative Properties

One of the most amazing features of the eye is its ability to repair itself and prevent infection after injury. Can-C™ drops support the healing process by keeping the eye well lubricated, delivering essential nutrients, enhancing DNA repair and reducing oxidative stress that could otherwise derail the natural healing process.

A higher (loading) dose of Can-C™ Eye Drops is recommended in the first few months of use to quickly re-establish optimal N-Acetyl-Carnosine (NAC) levels in the eyes of your pet: one drop to each eye – morning, noon and evening time for a total of three drops daily to each affected eye. The quicker these levels can be re-established in your pets’ eyes the sooner you will begin to see improvements in the appearance of the cataract as well as behavioral improvements. This initial (loading dosing period) lasts anywhere from 3 to 6 months depending upon the severity of your pets’ eye condition.

Once you begin to see notable improvements in the appearance of your pets’ cataract you may be confident that you have effectively re-established optimal N-acetyl-carnosine levels in your pets’ eyes, but the improvements don’t stop there. The good news is that once the NAC levels have been re-established to optimal levels it is very easy to keep them there at half the cost. After three to six months of consistent use, much less of the recommended Can-C dose is needed to effectively maintain these new levels, and the vision improvements will continue.

While many pet owners report improvements in their pets vision in as little as three months’ time generally the most dramatic improvements will be reached between six and twelve months of consistent use. Once optimal results have been achieved, the maintenance dose of only one to two drops daily will prevent the return of the Cataract(s) and will continue to support and improve the health of your pet’s eyes.

The benefits of Can-C™ eye-drops are long-lasting, however if the drops are discontinued, the same deficiency that allowed the ocular condition to form in the first place will likely return. Fortunately, by simply using a minimal amount of the product consistently, the good results can be maintained at less than half the initial cost.

Can-C™ eye drops initial loading dose: one drop applied to each eye morning, noon and evening time (3 total drops daily to each affected eye).

Can-C™ eye drops maintenance dose (general eye health support and prevention): After 3 to 6 months of use you will only need to use 1-2 drops of Can-C™ in each eye daily, with a one week pause from use every two months. The product will last a very long time at this level of usage.

Advanced Program Protocol
Nac-C Plus™ Capsules dose: (For dogs with diabetes or advanced cataract)give 1 capsules daily with food.. When used in conjunction with Can-C™ eye drops, Nac-C Plus capsules increase the length of time that Can-C™ eye drops stay active in the eye by inhibiting the breakdown of the L-carnosine that has been topically administered with the drops. This sustained effect significantly enhances free radical protection and decreases the oxidative environment within the eye, allowing for a faster healing response.

Independent clinical results are based on consistent daily use.

Can-C Clinical Study Proves Cataract Reversal in Dogs:

  • Improved visual behavior of the animals within weeks of treatment.
  • Cataract reversal starts from the periphery of the cataract followed by increased transparency of the lens.
  • 96% of canine eyes treated with N-acetyl-carnosine (Can-C) showed notable improvements.
  • Dogs with both immature and ripe cataracts showed significant visual improvement.

Can-C™ is a patented, proprietary form of N-acetylcarnosine (NAC)

Studies have shown that N-Acetyl-Carnosine (NAC) has a positive effect on lens clarity in people and dogs with age-related cataracts; it can help areas that were previously clouded to clear up and leads to improved vision, as well as helping to prevent the development of cataracts in the first place.(1) Cataracts tend to result from oxidative stress, and L-Carnosine has been shown to have an antioxidant impact on a cataract-affected lens, enhancing DNA repair and helping to prevent DNA strand breaks caused by UV radiation.(2) However, regular L-Carnosine eye drops cannot penetrate the eye. When applied to the eye's surface, N-Acetyl-Carnosine moves past the cornea into a part of the eye that is closer to the cataract, where it is metabolized into L-Carnosine. Thus, using NAC eye drops may help reverse or even prevent cataract progression, improving vision and quality of life.(3) L-Carnosine has been shown in clinical trials to be highly effective at protecting against and/or reversing cataracts and loss of vision.(4, 5) In fact, according to a Chinese trial on 96 patients aged 60 or older, Carnosine has a significant effect on primary senile cataracts, with a 100% effective rate. The impact rate for mature senile cataracts was 80%.(6) The primary ingredient in Can-C™ is a proprietary form of N-Acetyl-Carnosine, a highly specific intraocular form of Carnosine which when applied topically to the eye, acts as both a stabilizer and time-release carrier for the di-peptide L-Carnosine, safely delivering it into the aqueous humour of the eye. Here, in the fluid area surrounding the lens, L-Carnosine becomes most active in its ability to act as a natural and highly effective free radical scavenger, enhancing DNA repair and helping to prevent DNA strand breaks caused by UV radiation.(7) L-Carnosine's most important cataract-inhibiting activity may be its capacity to compete with proteins for binding sites on sugar molecules, thereby preventing the production of advanced glycated end products (protein crosslinks).(8-11) Dr. Mark Babizhayev, inventor of Can-C, demonstrated in research studies that using non-approved n-acetyl carnosine formulations will not help treat senile cataract due to lack of anti-cataract and antioxidant properties. Look for the approved Can-C hologram on the box of any Can-C eye drop product prior to applying to the eyes. The biological activity and therapeutic value of “carnosines” varies greatly depending on their source. For example, extractions from meat muscle components have minimal biological and antioxidant action due to heavy metal salts, proteins, and other impurities. Carnosine is difficult to purify chromatographically because it chelates divalent metal ions extensively making it difficult to retain its biological and antioxidant activities. Only the patented Can-C™ N-acetylcarnosine eye drops should be applied to the eyes. Innovative Vision Products (IVP), in collaboration with their Japanese partner, spent years researching to identify a specific purity level of N-acetyl-carnosine (NAC) that that would ensure both safety and optimal results. They have discovered, developed and patented a highly purified form of n-acetyl carnosine, which has excellent biological activity and has been proven effective in controlled human lens studies.
Note: After 6 months optimal N-Acetyl-Carnosine levels have been re-established in the eyes at which time a reduction to half the recommended amount provides ongoing support for continued vision improvement at half the cost!
  1. "Revival of the Lens Transparency with N-Acetylcarnosine", Babizhayev et. al., Current Drug Therapy, Volume 1, Issue 1, 2006, pg 91-116,
  2. Lou M F. Thiol regulation in the lens. J Ocul Pharmacol Ther 2000 Apr; 16(2):137-48.
  3. "N-Acetylcarnosine (NAC) Drops for Age-Related Cataract" Dubois & Bastawrous,
  4. Quinn P J, et al. Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med 1992; 13(5):379-444.
  5. Specht S, et al. Continuing damage to rat retinal DNA during darkness following light exposure. Photochem Photobiol 2000; 71(5):559-66.
  6. Wang AM, et al. Use of carnosine as a natural anti-senescence drug for human beings. Department of Biochemistry and Department of Neurobiology, Harbin Medical University, China 1999.
  7. Lou M F. Thiol regulation in the lens. J Ocul Pharmacol Ther 2000 Apr; 16(2):137-48.
  8. Ghodsi R, Kheirouri S. Carnosine and advanced glycation end products: a systematic review. Amino Acids. 2018 Sep;50(9):1177-1186. doi: 10.1007/s00726-018-2592-9. Epub 2018 Jun 1. PMID: 29858687.
  9. Michael A. Freund, Bingcan Chen, Eric A. Decker. The Inhibition of Advanced Glycation End Products by Carnosine and Other Natural Dipeptides to Reduce Diabetic and Age-Related Complications. 2018 July 27. doi: 10.1111/1541-4337.12376
  10. Abdelkader H, Longman M, Alany RG, et al. On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor? Oxid Med Cell Longev. 2016;2016:3240261.
  11. Liang J N, Chylack LT, Jr. Spectroscopic study on the effects of nonenzymatic glycation in human alpha-crystallin. Invest Ophthalmol Vis Sci. 1987;28(5):790-4.


The role of free radical-induced lipid oxidation in the development of cataracts in human and canine eyes

Study: Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes
Publication: Drugs R D . 2004;5(3):125-39. doi: 10.2165/00126839-200405030-00001.
Date published: January 30, 2022
Authors: Mark A Babizhayev, Anatoly I Deyev, Valentina N Yermakova, Igor V Brikman, Johan Bours
Summary: Cataract formation represents a serious problem in the elderly, with approximately 25% of the population aged >65 years and about 50% aged >80 years experiencing a serious loss of vision as a result of this condition. Not only do cataracts diminish quality of life, they also impose a severe strain on global healthcare budgets. In the US, 43% of all visits to ophthalmologists by Medicare patients are associated with cataract. Surgery represents the standard treatment of this condition, and 1.35 million cataract operations are performed annually in the US, costing 3.5 billion US dollars (year of costing, 1998). Unfortunately, the costs of surgical treatment and the fact that the number of patients exceeds surgical capacities result in many patients being blinded by cataracts worldwide. This situation is particularly serious in developing countries; worldwide 17 million people are blind because of cataract formation, and the problem will grow in parallel with aging of the population. In any event, surgical removal of cataracts may not represent the optimal solution. Although generally recognised as being one of the safest operations, there is a significant complication rate associated with this surgical procedure. Opacification of the posterior lens capsule occurs in 30-50% of patients within 2 years of cataract removal and requires laser treatment, a further 0.8% experience retinal detachments, approximately 1% are rehospitalised for corneal problems, and about 0.1% develop endophthalmitis. Although the risks are small, the large number of procedures performed means that 26,000 individuals develop serious complications as a result of cataract surgery annually in the US alone. Thus, risk and cost factors drive the investigation of pharmaceutical approaches to the maintenance of lens transparency. The role of free radical-induced lipid oxidation in the development of cataracts has been identified. Initial stages of cataract are characterised by the accumulation of primary (diene conjugates, cetodienes) lipid peroxidation (LPO) products, while in later stages there is a prevalence of LPO fluorescent end-products. A reliable increase in oxiproducts of fatty acyl content of lenticular lipids was shown by a direct gas chromatography technique producing fatty acid fluorine-substituted derivatives. The lens opacity degree correlates with the level of the LPO fluorescent end-product accumulation in its tissue, accompanied by sulfhydryl group oxidation of lens proteins due to a decrease of reduced glutathione concentration in the lens. The injection of LPO products into the vitreous has been shown to induce cataract. It is concluded that peroxide damage of the lens fibre membranes may be the initial cause of cataract development. N-acetylcarnosine (as the ophthalmic drug Can-C), has been found to be suitable for the nonsurgical prevention and treatment of age-related cataracts. This molecule protects the crystalline lens from oxidative stress-induced damage, and in a recent clinical trial it was shown to produce an effective, safe and long-term improvement in sight. When administered topically to the eye in the form of Can-C, N-acetylcarnosine functions as a time-release prodrug form of L-carnosine resistant to hydrolysis with carnosinase. N-acetylcarnosine has potential as an in vivo universal antioxidant because of its ability to protect against oxidative stress in the lipid phase of biological cellular membranes and in the aqueous environment by a gradual intraocular turnover into L-carnosine. In our study the clinical effects of a topical solution of N-acetylcarnosine (Can-C) on lens opacities were examined in patients with cataracts and in canines with age-related cataracts. These data showed that N-acetylcarnosine is effective in the management of age-related cataract reversal and prevention both in human and in canine eyes.


Treatment with 1% N-acetylcarnosine (NAC) protects telomeres to prevent and dissolve mature cataracts in dogs.

Study: Biomarkers of oxidative stress and cataract. Novel drug delivery therapeutic strategies targeting telomere reduction and the expression of telomerase activity in the lens epithelial cells with N-acetylcarnosine lubricant eye drops: anti-cataract which helps to prevent and treat cataracts in the eyes of dogs and other animals
Publication: Curr Drug Deliv . 2014;11(1):24-61. doi: 10.2174/15672018113106660062.
Date published: January 30, 2022
Authors: Mark A Babizhayev, Yegor E Yegorov
Summary: Cataracts in small animals are shown to be at least partially caused by oxidative damage to lens epithelial cells (LECs) and the internal lens; biomarkers of oxidative stress in the lens are considered as general biomarkers for life expectancy in the canine and other animals. Telomeres lengths and expressed telomerase activity in canine LECs may serve as important monitors of oxidative damage in normal LECs with documented higher levels of telomerase activity in cataractous LECs during cells’ lifespan. Loss of functional telomere length below a critical threshold in LECs of canines during the effect of UV and chronic oxidative stress or metabolic failure, can activate programs leading to LEC senescence or death. Telomerase is induced in LECs of canines at critical stages of cataractogenesis initiation and exposure to oxidative stress through the involvement of catalytically active prooxidant transition metal (iron) ions. This work documents that transition metal ions (such as, ferrous ions- catalytic oxidants) might induce premature senescence in LECs of canines, telomere shortening with increased telomerase activity as adaptive response to UV light, oxidative and metabolic stresses. The therapeutic treatment with 1% N-acetylcarnosine (NAC) prodrug delivery is beneficial for prevention and dissolution of ripe cataracts in canines. This biological activity is based on the findings of ferroxidase activity pertinent to the dipeptide carnosine released ophthalmically from NAC prodrug of L-carnosine, stabilizing properties of carnosine on biological membranes based on the ability of the imidazole-containing dipeptides to interact with lipid peroxidation products and reactive oxygen species (ROS), to prevent membrane damage and delute the associated with membrane fragements protein aggregates. The advent of therapeutic treatment of cataracts in canines with N-acetylcarnosine lubricant eye drops through targeting the prevention of loss of functional telomere length below a critical threshold and “flirting” with an indirect effect with telomerase expression in LECs of canines during the effects of UV, chronic oxidative stress increases the successful rate of cataract management challenges in home veterinary care.

Are Can-C™ Eye Drops Really safe for animals?
Yes, N-Acetylcarnosine (Can-C™) eye drops have been researched in humans and in animals for over ten years and used for more than five years by thousands in Russia, China, Europe and the US without any side effects or complications. In fact the antioxidant properties of N-acetylcarnosine (Can-C™) apear to soothe and improve the overall health of dog eyes. Can-C™ is manufactured in a GMP (Good Manufacturing Procedures) facility per Dr. Mark Babizhayev’s protocols and FDA guidelines, however only the lubricants (Carboxymethylcellulose sodium) and (glycerin) are approved by the FDA for ophthalmic use, Can-C is not yet FDA approved for the treatment of canine cataracts as the clinical trials have been conducted primarily in Russia over the last decade; therefore N-Acetylcarnosine (1%) is listed as an inactive ingredient on the label.
I have been told that my dog is too small for cataract surgery. Can I use these cataract eye drops for him?
Can-C is a great solution for animals that do not have surgery as an option, and has been successfully used to treat the cataracts of domestic animals of all sizes from Chihuahuahs to the largest of breeds.
Are there any potential side effects?
A: With this formula, utilized in 10 years of human and animal clinical trials, there have been no reported side effects or contra-indications, even when used everyday for up to 2 years. Generally use of this natural anti-oxidant formulation is soothing and improves the overall environment in the eye.
Click here for additional FAQ's
“I just wanted to contact you to let you know your product; Can C drops for dogs, is fantastic! In the few days, I have been using them; his eyes have cleared up, not entirely but enough to be able to see his blue eyes again. I’m just amazed at how quickly it is working on him and to be able to see him more active and be able to see somewhat it’s a start.” Dianne Lassley
I purchased the n-acetylcarnosine eye drops for my 10 yr old standard poodle Missy and have been applying the drops for a little over 3 months. Amazingly her eyes are now clear it has been a truly incredible experience to watch. She is more like her old self with renewed confidence and enthusiasm for life. Also our Vet was extremely impressed with Missy's improvements. We cannot begin to thank you enough for this incredible product.* DC Jackson MO
Click here for additional Reviews

Bundles containing Can-C Eye Drops for Dogs

Contact us

Any questions? We’re here to help.